Sacituzumab Govitecan (SG)+Toripalimab

DRUG2 trials

Sponsors

Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital

Conditions

NSCLC (Non-small Cell Lung Cancer)TNBC

Phase 2

Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC

Not yet recruitingNCT07438600

Tianjin Medical University Cancer Institute and HospitalNSCLC (Non-small Cell Lung Cancer)

Start: 2026-02-24End: 2028-02-28Target: 38Updated: 2026-03-27

Unknown Phase

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

RecruitingNCT06991790

Peking University Cancer Hospital & InstituteTNBC

Start: 2025-05-01End: 2028-05-01Target: 51Updated: 2025-05-28